Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. (2019)


No abstract provided

Bibliographic Information

Digital Object Identifier:

PubMed Identifier: 30796818

Publication URI:

Type: Journal Article/Review

Volume: 220

Parent Publication: The Journal of infectious diseases

Issue: 1

ISSN: 0022-1899